Abstract:A RECENT ANNOUNCEMENT by the American Medical Association that it proposes to assume leadership in the development of a national health policy primarily within the private sector could signal a watershed in the national approach to dealing with the compounding problems the nation faces in health care. That task will not be easy. Policymakers and institutions in both the public and private sectors have long been active in this field, yet no generally acceptable, workable national health policy for the long term has yet emerged. The timing for such a new approach seems particularly auspicious. Americans seem more focused on health and its enhancement now than at any time in their history. For some decades we have been spending more and more for health and health care until now nearly 10 percent of the gross national product is spent for these purposes. Patient care in the United States is generally conceded to be the best in the world. And, significantly, as a nation we seem for the time being at least to have rejected centralized, nationalized, government controlled health care. But all is not well. There is an obvious need for a long-term national health policy that is acceptable and workable, and right now there is a relative vacuum of effective leadership in this field. The opportunity should be seized. The time may come when the nation may have another, perhaps grander, objective than health. It is noteworthy that this health care system has long since passed the point where doctors, hospitals or any other single segment of it (and this includes government) can ever hope to control it without the help and cooperation of the other segments. There are some who still believe that government could of course do so, but the evidence to date is that this is not likely to be the case. So far unilateral government initiatives in health care have fallen far short of what needs to be done and generally seem to have caused more problems than they have solved. Could it be that the health care enterprise is developing into something of a new phenomenon in America-or anywhere else for that matter? Could it be that for the first time we are starting to see the massive fiscal and human dimensions of what can occur when new science and expensive technology are rather quickly developed and put to widespread human use, and the intricate professional, technologic, social, economic and political interdependencies that ensue? For many reasons this seems to be a truly new phenomenon, which has surfaced first in the health field, but is no doubt destined to turn up in other fields as well, when comparable conditions develop. For nearly 40 years the nation has given special attention and special support from both public and private sources to biomedical research, to health professional education and to making the benefits of rapidly accumulating new knowledge and new technology readily available to as many people as possible. As a result a new kind of system of interdependencies has come into being that is as yet poorly understood and certainly does not behave according to the rules for simpler systems. As has been said, if you push the health care system in one place it just bulges somewhere else. It is suggested that this new kind of system is one of interdependencies among relatively independent and autonomous parts. This in turn suggests that if there is to be policy and direction, it will need to be developed internally within the system with involvement and consensus among all or most of the essential autonomous and independent, yet interdependent, parts. The AMA iS to be commended for its proposed approach to developing a national health policy. It plans to involve "such organizations as specialty societies, the American Hospital Association, Blue Cross-Blue Shield, the American Dental Association, the American Nurses Association, the National Medical Association, The Health Insurance Association of America, representatives of the business community such as Chambers of Commerce and The Business Round Table, representa-

What standards and terms of employment should respiratory practitioners with a special interest expect from an employing organisation?

Activities of Serven Fungal Endophytes from Cucumber Plants to the Second Stage Juveniles of Meloidogyne Incognita

The Identification of Biocontrol Bacterium K-8 and Its Biological Control Against Meloidogyne incognita

The Biocontrol Functions of Bacillus velezensis Strain Bv-25 Against Meloidogyne incognita

Nematicidal Volatiles from Bacillus atrophaeus GBSC56 Promote Growth and Stimulate Induced Systemic Resistance in Tomato against Meloidogyne incognita

Antagonistic Efficacy of Symbiotic Bacterium Xenorhabdus sp. SCG against Meloidogyne spp

Nematicidal potential of Streptomyces antibioticus strain M7 against Meloidogyne incognita

Characterization of Nematicidal Activity and Nematode-Toxic Metabolites of a Soilborne Brevundimonas bullata Isolate

Bacillus thuringiensis Cry5, Cry21, App6 and Xpp55 proteins to control Meloidogyne javanica and M. incognita

Suppression of Meloidogyne Javanica by Antagonistic and Plant Growth-Promoting Rhizobacteria

Microbial landscapes of the rhizosphere soils and roots of Luffa cylindrica plant associated with Meloidogyne incognita

Biocontrol efficacy of endophytic fungus, Acremonium sclerotigenum, against Meloidogyne incognita under in vitro and in vivo conditions

Biocontrol of Meloidogyne spp. in Solanum lycopersicum using a dual combination of Bacillus strains

Endophytic Bacillus spp. Mediated Plant Growth Promotion of Tomato Seedlings and Suppression of Meloidogyne incognita and Fusarium oxysporum Disease Complex

Bacillus firmus Strain I-1582, a Nematode Antagonist by Itself and Through the Plant

Direct effects of Xenorhabdus spp. cell-free supernatant on Meloidogyne incognita in tomato plants and its impact on entomopathogenic nematodes

case-control study . cancer of the pancreas : a Occupational risk factors for

Nematicidal Activity of Burkholderia arboris J211 Against Meloidogyne incognita on Tobacco

Mg2+ Is Not Catalytically Required in the Intrinsic and Kirromycin-stimulated GTPase Action of Thermus thermophilus EF-Tu*

Optimal teicoplanin dosage regimens for methicillin-resistant Staphylococcus aureus infections in endocarditis patients and renal failure patients

The AMA and a National Health Policy.